The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7121-7126

  Nishiyama, Tsutomu ^a   Hashimoto, Yutaka ^b   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; CORTICOTROPIN; FLUTAMIDE; FOLLITROPIN; GONADORELIN AGONIST; HYDROCORTISONE; LUTEINIZING HORMONE; PRASTERONE; PRASTERONE SULFATE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CASTRATION; CONTROLLED STUDY; DERIVATIZATION; ELECTROSPRAY MASS SPECTROMETRY; HORMONE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL; TISSUE LEVEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; CHROMATOGRAPHY, LIQUID; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TESTOSTERONE 5-ALPHA-REDUCTASE; TIME FACTORS;

EID: 8444231965     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0913     Document Type: Article

References (24)

1. Huggins C, Hodges CV. Studies on prostate cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
2. Hammond GL. Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. J Endocrinol 1978;78:7-19.
3. Geller J, Albert JD. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol Res 1987;15:151-3.
4. Forti G, Salerno R, Moneti G, et al. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J Clin Endocrinol Metab 1989;68:461-8.
5. Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989;32:695-8.
6. Labrie F, Belanger A, Dupont A, Luu-The V, Simard J, Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin Investig Med 1993;16:475-92.
7. Nakagawa Y, Hashimoto Y. Polar derivatization of 5 alpha- dihydrotestosterone and sensitive analysis by semimicro-LC/ESI-MS. J Mass Spectrum Soc Jpn 2002;50:330-6.
8. Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
9. Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD. Enzymes of androgen formation and degradation in the human prostate. Ann NY Acad Sci 1990;595:53-66.
10. Koh E, Kanaya J, Namiki M. Adrenal steroids in human prostatic cancer cell lines. Arch Androl 2001;46:117-25.
11. Koh E, Noda T, Kanaya J, Namiki M. Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 2002;53:154-9.
12. Balzano S, Cappa M, Migliari R, et al. The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J Endocrinol Investig 1988;11:693-6.
13. Ayub M, Levell MJ. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue. Clin Endocrinol (Oxf) 1990;32:329-39.
14. Carlstrom K, Pousette A, Stege R. Flutamide has no effect on adrenal androgen response to acute ACTH stimulation in patients with prostatic cancer. Prostate 1990;17:219-25.
15. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000;355:1491-8.
16. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int 2001;87:806-13.
17. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
18. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002;60:115-9.
19. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-8.
20. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6.
21. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-8.
22. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
23. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
24. Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001;6:177-82.